MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Sarepta Therapeutics Depreciation & Amortization 2011-2026 | SRPT
Annual Depreciation & Amortization Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.5 M | 37.7 M | 44.4 M | 41.9 M | 38 M | 26.9 M | 24.5 M | 12.2 M | 8.09 M | 5.61 M | 5.25 M | 3.69 M | 1.28 M | 1.52 M | 1.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.5 M | 1.28 M | 19.8 M |
Quarterly Depreciation & Amortization Sarepta Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 677 K | 667 K | 9.98 M | - | 602 K | 601 K | 8.74 M | - | 439 K | 179 K | 11.3 M | - | 178 K | 179 K | 10.7 M | - | 27.9 M | 179 K | 8.93 M | 165 K | 19.6 M | 13 M | 6.53 M | 200 K | 17.9 M | 11.1 M | 4.88 M | 216 K | 8.72 M | 5.12 M | 2.25 M | 216 K | 5.97 M | 3.41 M | 1.64 M | 29 K | 3.95 M | 2.87 M | 1.4 M | - | 3.88 M | 2.57 M | 1.28 M | - | 2.53 M | 1.48 M | 523 K | - | 998 K | 711 K | 451 K | - | 1.09 M | 715 K | 353 K | - | 763 K | 490 K | 239 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.9 M | 29 K | 4.17 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Catalyst Pharmaceuticals
CPRX
|
375 K | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
233 K | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Cardiff Oncology
CRDF
|
364 K | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.99 M | $ 20.25 | -0.54 % | $ 2.83 B |  France |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
5.38 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Equillium
EQ
|
116 K | $ 2.0 | -0.5 % | $ 115 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
12.9 M | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Forte Biosciences
FBRX
|
64 K | $ 26.15 | -1.1 % | $ 339 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
|
Foghorn Therapeutics
FHTX
|
3.33 M | $ 4.75 | -2.59 % | $ 299 M | USA |
 |
Amicus Therapeutics
FOLD
|
7.46 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.52 | -0.56 % | $ 237 B | Britain |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Fulcrum Therapeutics
FULC
|
1.39 M | $ 7.45 | -4.85 % | $ 472 K | USA |
 |
Galectin Therapeutics
GALT
|
1 K | $ 2.38 | -7.03 % | $ 152 M | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | USA |
 |
Gilead Sciences
GILD
|
370 M | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
42 K | $ 0.54 | 4.26 % | $ 503 K |  Israel |
 |
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |